Prokidney Corp.
PROK Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.52
KIRA · Stoqly’s AI analyst, in plain words
- Prokidney Corp. had $0.9M of revenue in fiscal 2025, up 1,075.0% on the year before.
- Its operating margin was −18,477.8%, up 223,201.1 pts: of every 100 in sales, about −18,478 is left after running the business.
- Prokidney Corp. lost $69.0M in fiscal 2025.
- Free cash flow was −$135M in fiscal 2025, −15,152.6% of revenue.
- Prokidney Corp. returned $0.0M to shareholders in fiscal 2025.
Market cap
—
P/E
—
Revenue
$0.9M
Net income
−$69.0M
Free cash flow
−$135M
Operating margin
−18,477.8%
Prokidney Corp. in 30 seconds · fiscal 2025
Are sales growing?
+1,075.0%
Yes. Sales grew 1,075.0% last year.
Does it make a profit?
−7,725.2%
No. It lost money last year.
Does profit turn into cash?
−15,152.6%
No. It spent more cash than it brought in.
What Prokidney Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- PROKIDNEY CORP.
- CIK
- 0001850270
Prokidney Corp. · PROK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.0M | $0.1M | $0.9M |
| Revenue growth | — | — | — | — | 1,075.0% |
| Operating margin | — | — | — | −241,678.9% | −18,477.8% |
| Net income | −$55.1M | −$148M | −$35.5M | −$61.2M | −$69.0M |
| Net margin | — | — | — | −80,507.9% | −7,725.2% |
| Diluted EPS | — | −$0.23 | — | — | — |
| Cash | |||||
| Cash from operations | −$50.3M | −$77.1M | −$90.1M | −$126M | −$120M |
| Capital expenditure | $5.2M | $1.8M | $34.2M | $29.5M | $15.2M |
| Free cash flow | −$55.5M | −$78.9M | −$124M | −$156M | −$135M |
| FCF margin | — | — | — | −205,078.9% | −15,152.6% |
| Share buybacks | $0.0M | $0.0M | $9.5M | $0.0M | $0.0M |
| Debt and strength | |||||
| Cash and short-term investments | $20.6M | $490M | $60.6M | $99.1M | $109M |
| Shareholders' equity | $26.9M | −$1.1B | −$1.1B | −$995M | −$1.0B |
| Current ratio | 2.2x | 46.4x | 14.9x | 10.9x | 9.1x |
| Interest coverage | — | −711.7x | −12,626.8x | −20,408.4x | −41,251.8x |
| Returns and quality | |||||
| Return on equity | −299.9% | — | — | — | — |
| Return on tangible equity | −208.2% | — | — | — | — |
| Altman Z'' | −17.7 | −90.9 | −45.5 | −32.8 | −41.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Prokidney Corp. · PROK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.52 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001850270). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.